We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

110 hedge funds and large institutions have $330M invested in Trevi Therapeutics in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 24 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

96% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 24

70% more capital invested

Capital invested by funds: $194M → $330M (+$135M)

18% more funds holding

Funds holding: 93 → 110 (+17)

8.89% more ownership

Funds ownership: 80.07% → 88.95% (+8.9%)

13% less call options, than puts

Call options by funds: $927K | Put options by funds: $1.06M

Holders
110
Holders Change
+17
Holders Change %
+18.28%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
26
Increased
47
Reduced
24
Closed
7
Calls
$927K
Puts
$1.06M
Net Calls
-$134K
Net Calls Change
-$569K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$13.3M
2
FLSM
Frazier Life Sciences Management
California
+$10.5M
3
SL
Siren LLC
Connecticut
+$9.3M
4
WP
Woodline Partners
California
+$8.34M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$8M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$6.9M
2
LGM
Logos Global Management
California
-$4.8M
3
RCMNY
Rubric Capital Management (New York)
New York
-$2.63M
4
ABG
Ally Bridge Group
New York
-$1.73M
5
LCM
Landscape Capital Management
New Jersey
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Mirae Asset Global Investments
101
Mirae Asset Global Investments
South Korea
$10.9K +$8.2K +2,561 New
TRCT
102
Tower Research Capital (TRC)
New York
$10.9K -$4K -1,251 -32%
RS
103
R Squared
Hong Kong
$9.56K +$7.43K +2,320 New
GFM
104
GF Fund Management
China
$6.65K +$5.17K +1,614 New
AB
105
Amalgamated Bank
New York
$6K – – –
SCM
106
Sterling Capital Management
North Carolina
$3.33K +$2.24K +700 +642%
SS
107
SBI Securities
Japan
$280 +$218 +68 New
FFA
108
Farther Finance Advisors
California
$227 – – –
NS
109
NBC Securities
Alabama
$8 -$6.4K -1,998 -100%
SC
110
Shay Capital
New York
– -$314K -93,962 Closed
FAM
111
Fred Alger Management
New York
– -$256K -76,544 Closed
B
112
Bailard
California
– -$117K -35,133 Closed
Jane Street
113
Jane Street
New York
– -$110K -32,929 Closed
Federated Hermes
114
Federated Hermes
Pennsylvania
– -$2K -598 Closed
CPA
115
Capital Performance Advisors
California
– -$448 -134 Closed
Nisa Investment Advisors
116
Nisa Investment Advisors
Missouri
– -$281 -84 Closed
Carson Wealth (CWM LLC)
117
Carson Wealth (CWM LLC)
Nebraska
– -$13 -4 -5%
1 2 3 4
5

TRVI Hedge Fund Activity: Q4 2024 in Review

110 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2024, worth a combined $330M — up 70% from $194M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new TRVI positions and 7 closed out — a net gain of 19 holders — while 47 added to existing stakes and 24 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $13.3M. The largest seller was VR Adviser, cutting an estimated $6.9M.

  • 110 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2024, up from 93 in Q3 2024.
  • Funds reported $330M of Trevi Therapeutics stock for Q4 2024, up 70% quarter-over-quarter.
  • 26 funds opened new Trevi Therapeutics positions in Q4 2024 and 7 closed out, a net change of +19 holders.
  • The largest Trevi Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $13.3M added.
  • The largest Trevi Therapeutics seller in Q4 2024 was VR Adviser, an estimated $6.9M sold.

Based on aggregated 13F filings for Q4 2024.